[Pubmed] Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case
Posté : 16 juil. 2026 12:00
Front Immunol. 2026 Jul 1;17:1854332. doi: 10.3389/fimmu.2026.1854332. eCollection 2026.
ABSTRACT
Tislelizumab, an immune checkpoint inhibitor, is widely used in the treatment of various malignancies; however, its immune-related adverse events(irAEs) require careful attention. Here, we report a case of a patient with recurrent urothelial carcinoma who developed myositis and myasthenia-like manifestations after receiving tislelizumab, despite negative myasthenia-associated antibodies. The patient's symptoms gradually alleviated following treatment with corticosteroids and intravenous immunoglobulin. To our knowledge, antibody-negative myasthenia gravis associated with tislelizumab has been scarcely documented. This case highlights that in patients receiving tislelizumab, early pharmacological intervention should be considered when typical myasthenia-like manifestations occur, even in the absence of antibody positivity, emphasizing the importance of prompt recognition and timely treatment.
PMID:42459703 | PMC:PMC13368925 | DOI:10.3389/fimmu.2026.1854332
Source: https://pubmed.ncbi.nlm.nih.gov/4245970 ... 3&v=2.20.0